scholarly journals Single-nucleus chromatin accessibility and transcriptomic characterization of Alzheimer’s disease

2021 ◽  
Author(s):  
Samuel Morabito ◽  
Emily Miyoshi ◽  
Neethu Michael ◽  
Saba Shahin ◽  
Alessandra Cadete Martini ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Chromatin Accessibility ◽  
Single Nucleus

scholarly journals Characterization of the chromatin accessibility in an Alzheimer’s disease (AD) mouse model

2020 ◽  
Vol 12 (1) ◽  
Author(s):  
Yaqi Wang ◽  
Xiaomin Zhang ◽  
Qiao Song ◽  
Yuli Hou ◽  
Jing Liu ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Mouse Model ◽  
Chromatin Accessibility ◽  
Ad Mouse Model

scholarly journals Characterization of the chromatin accessibility in Alzheimer’s disease

2020 ◽  
Vol 34 (S1) ◽  
pp. 1-1
Author(s):  
Yaqi Wang ◽  
Qiao Song ◽  
Xiaomin Zhang ◽  
Yuli Hou ◽  
Peichang Wang
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Chromatin Accessibility

scholarly journals Molecular characterization of selectively vulnerable neurons in Alzheimer’s Disease

2020 ◽  
Author(s):  
Kun Leng ◽  
Emmy Li ◽  
Rana Eser ◽  
Antonia Piergies ◽  
Rene Sit ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Entorhinal Cortex ◽  
Neuronal Loss ◽  
Selective Vulnerability ◽  
Brain Regions ◽  
Neuronal Populations ◽  
Expression Of Genes ◽  
Single Nucleus

ABSTRACTAlzheimer’s disease (AD) is characterized by the selective vulnerability of specific neuronal populations, the molecular signatures of which are largely unknown. To identify and characterize selectively vulnerable neuronal populations, we used single-nucleus RNA sequencing to profile the caudal entorhinal cortex and the superior frontal gyrus – brain regions where neurofibrillary inclusions and neuronal loss occur early and late in AD, respectively – from postmortem brains spanning the progression of AD-type tau neurofibrillary pathology. We identified RORB as a marker of selectively vulnerable excitatory neurons in the entorhinal cortex, and subsequently validated their depletion and selective susceptibility to neurofibrillary inclusions during disease progression using quantitative neuropathological methods. We also discovered an astrocyte subpopulation, likely representing reactive astrocytes, characterized by decreased expression of genes involved in homeostatic functions. Our characterization of selectively vulnerable neurons in AD paves the way for future mechanistic studies of selective vulnerability and potential therapeutic strategies for enhancing neuronal resilience.

The Therapeutic Potential of Purinergic Receptors in Alzheimer’s Disease and Promising Therapeutic Modulators

2020 ◽  
Vol 20 ◽  
Author(s):  
Lili Pan ◽  
Yu Ma ◽  
Yunchun Li ◽  
Haoxing Wu ◽  
Rui Huang ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Purinergic Receptors ◽  
Therapeutic Potential ◽  
Purinergic Signaling ◽  
Memory Loss ◽  
Related Research ◽  
Central Nervous System Disorders ◽  
G Protein Coupled

Abstract:: Recent studies have proven that the purinergic signaling pathway plays a key role in neurotransmission and neuromodulation, and is involved in various neurodegenerative diseases and psychiatric disorders. With the characterization of the subtypes of receptors in purinergic signaling, i.e. the P1 (adenosine), P2X (ion channel) and P2Y (G protein-coupled), more attentions were paid to the pathophysiology and therapeutic potential of purinergic signaling in central nervous system disorders. Alzheimer’s disease (AD) is a progressive and deadly neurodegenerative disease that is characterized by memory loss, cognitive impairment and dementia. However, as drug development aimed to prevent or control AD follows a series of failures in recent years, more researchers focused on the neuroprotection-related mechanisms such as purinergic signaling in AD patients to find a potential cure. This article reviews the recent discoveries of purinergic signaling in AD, summaries the potential agents as modulators for the receptors of purinergic signaling in AD related research and treatments. Thus, our paper provided an insight for purinergic signaling in the development of anti-AD therapies.

scholarly journals Characterization of monomeric and soluble aggregated Aβ in Down’s syndrome and Alzheimer’s disease brains

2021 ◽  
Vol 754 ◽  
pp. 135894
Author(s):  
Eleni Gkanatsiou ◽  
Charlotte Sahlin ◽  
Erik Portelius ◽  
Malin Johannesson ◽  
Linda Söderberg ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Down's Syndrome ◽  
Down’S Syndrome

scholarly journals Identification and characterization of OGG1 mutations in patients with Alzheimer's disease

2007 ◽  
Vol 35 (8) ◽  
pp. 2759-2766 ◽  
Author(s):  
Guogen Mao ◽  
Xiaoyu Pan ◽  
Bei-Bei Zhu ◽  
Yanbin Zhang ◽  
Fenghua Yuan ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Identification And Characterization

scholarly journals Characterization of monomeric and soluble aggregated Aβ in Down’s syndrome and Alzheimer’s disease brains

2020 ◽  
Vol 16 (S2) ◽  
Author(s):  
Eleni Gkanatsiou ◽  
Charlotte Sahlin ◽  
Erik Portelius ◽  
Malin Johannesson ◽  
Linda Söderberg ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Down's Syndrome ◽  
Down’S Syndrome
Sign in / Sign up

Export Citation Format

Share Document